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Abstract
Objective: To evaluate the relationship between symptom and functional improvement and remission in children and
adolescents with attention-deficit/hyperactivity disorder (ADHD) enrolled in an 11-week open-label dose-optimization phase
of an methylphenidate extended release (MPH-MLR) pivotal study.
Methods: Assessments included the Weiss Functional Impairment Rating Scale-Parent (WFIRS-P) and ADHD Rating Scale,
Fourth Edition (ADHD-RS-IV). Definitions included the following: symptom improvement (‡30% decrease in ADHD-RS-
IV total score); symptom remission (ADHD-RS-IV total score £18); functional improvement (decrease in WFIRS-P total
score ‡0.25 [minimally important difference]); and functional remission (WFIRS-P total score £0.65).
Results: Two hundred children completed the open-label phase. At initial assessment, functional impairment was evident
across all WFIRS-P domains and similar between children and adolescents. Those who were treatment naive had more
functional impairment (WFIRS-P total: 0.82 vs. 0.70, p = 0.02). Significant improvements in all WFIRS-P domains were
noted at open-label end ( p < 0.001), with the largest improvement in Learning. At open-label end, 94% of children and
adolescents demonstrated symptom improvement, of which 57% also showed functional improvement, and 75% of children
and adolescents showed symptom remission, of which 81% also showed functional remission.
Conclusions: Children and adolescents treated with MPH-MLR showed moderate-to-large improvement in functioning during
3 months of treatment, both overall and in specific domains. However, a significant number of those who would be considered
symptomatic responders failed to show improvement in functioning or continue to have significant functional impairment.
Treatment with MPH-MLR showed that both symptomatic and functional remission are achievable goals. Identification of
children and adolescents who have been successfully treated for their symptoms, but continue to suffer functional impairment,
will allow us to offer additional targeted treatment interventions over and above medication to address residual difficulties.
Keywords: attention-deficit/hyperactivity disorder (ADHD), Weiss Functional Impairment Rating Scale-Parent (WFIRS-P),
MPH-MLR, functional impairment
Introduction
Attention-deficit/hyperactivity disorder (ADHD), asdefined by the Diagnostic and Statistical Manual of Mental
Disorders-Fifth Edition (DSM-5), includes behavioral symptoms
and functional impairments that extend across more than one setting
(American Psychiatric Association 2013). Thus, ADHD is a multi-
dimensional disorder requiring that evaluations of new therapies in-
clude a variety of assessments (Epstein and Weiss 2012). Although
the symptoms of ADHD (inattention, hyperactivity, and impulsivity)
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are generally well recognized, it is often functional impairment that
results in entry into the healthcare system for patients and their
families (Epstein and Weiss 2012). Functional impairment en-
compasses the inability to complete tasks at school or at home, has a
substantial impact on a child’s or adolescent’s ability to have
meaningful friendships, and can have a negative impact on family
relationships (Buitelaar and Medori 2010).
The primary endpoint in evaluations of new ADHD medications
is usually symptom improvement or symptom remission to identify
responder status. Although there have been various definitions of
these categories, symptom improvement is usually defined as a
30% decrease in symptoms, or much improved (2) or very much
improved (1) on the Clinical Global Impressions-Improvement
(CGI-I) scale (Guy 1976). Symptom remission has been described
as either a 40% or even 50% improvement in symptoms or a final
mean symptom score of 1.0 (Swanson et al. 2001). It should be
noted that these definitions have been shown to be highly correlated
with one another (Mattingly et al. 2017).
Nonetheless several important caveats should be considered. The
concept of ‘‘remission,’’ borrowed originally from the depression
literature as a predictor of relapse (Quitkin et al. 2005), is not
consistent with the concept of ADHD as a neurodevelopmental
disorder. In addition, the concept of improvement and remission
was originally developed by Swanson et al. (2001) on somewhat
arbitrary criteria with no reference to normative symptom scores
in the population. For example, normative values for adolescent
girls are much lower than for preschool boys, and using the same
definition of remission for both may be inappropriate (Molina
et al. 2009). We have adopted the consensually agreed upon term
‘‘remission’’ to indicate a robust improvement in symptoms or
functioning, without necessarily implying that the patient is free
of difficulty or at risk for return of symptoms given a change in
treatment or circumstances (Molina et al. 2009).
There is also a conceptual difference between how much better
symptoms are (i.e., percentage improvement) and how well the
patient is at endpoint. To illustrate this difference, if a patient has
a baseline score of 54 and shows full ‘‘response’’ status because
he is 50% improved, his final score at endpoint is 27, which might
still be clinically significant, especially if the residual symp-
toms were concentrated in either the inattentive or hyperactive/
impulsive domains. Similarly, a patient with a baseline symptom
score of 27, who has a 30% improvement, might end up in the
normal range. This means that definitions of outcome need to look
at percentage change as well as endpoint and improvement as well
as remission, and be anchored outside of core symptoms in treat-
ment targets relevant to the patient’s presenting problem or func-
tional impairment.
These definitions of symptom improvement and remission do not
reference functional improvement or remission. Information re-
garding the existence of a treatment effect, statistical significance, or
the magnitude of significance as measured by effect size has no
bearing on clinical significance or impact on a patient’s life. Clinical
significance has been variously defined as a level of change that is
recognizable by others, normative levels of functioning by the end of
treatment, or failure to meet diagnostic criteria ( Jacobson and Truax
1991). To determine clinical significance within a treatment model, it
is also necessary to show both that the change reflects more than the
fluctuations of the measure (Reliable Change Index) and the change
indicates the patient is no longer dysfunctional, is in the normal range
of functioning, or is functioning closer to the mean of the functional
population than the mean of the dysfunctional population (Jacobson
and Truax 1991). While these are very different definitions of clinical
significance, they are all based on establishing a functional outcome
standard that goes beyond symptoms.
The focus of this study was to look at symptom improvement and
remission by referencing these predefined outcomes against im-
provement and remission in functional impairment. There are no
studies we are aware of that have empirically examined whether
patients who are classified as ‘‘responders’’ are actually doing well as
defined by a normative standard for functional well-being. While
some research reflecting the impact of specific compounds on
functional impairment has been conducted (Banaschewski et al.
2013), there remains a need to better understand how a pharma-
cotherapeutic intervention for ADHD might impact functional out-
comes and the relationship between change in symptoms and change
in functioning. Recent research has consistently demonstrated, par-
ticularly in pharmacological clinical trials, that the relationship be-
tween change in symptoms, functioning, and quality of life is modest,
and that inclusion of multiple outcomes is necessary to provide the
clinician with information needed to determine whether and what
type of further intervention the patient needs.
Methods
Data for this post hoc analysis were taken from a randomized,
double-blind, placebo-controlled, parallel, forced-dose study (Clin-
icalTrials.gov identifier NCT01239030) evaluating the safety and
efficacy of four dose levels of methylphenidate extended release
(MPH-MLR; 10, 15, 20, and 40 mg) compared with placebo in 230
children (67% male) and adolescents (6–18 years of age) with
ADHD. The primary outcomes and complete study design have been
published previously (Wigal et al. 2015). Briefly, this was a four-
phase study that included the following: screening, 1-week forced-
dose double blind, 11-week open label, and follow-up. The primary
outcomes and complete study design have been published previously
(Wigal et al. 2015). Since the 1-week double-blind period was shorter
than the observation period and past study of sensitivity to change of
the Weiss Functional Impairment Rating Scale (WFIRS), the data
reported here are based on the open-label phase. Children and ado-
lescents with all ADHD subtypes (except Not Otherwise Specified)
were included in this study (Wigal et al. 2015). A baseline ADHD
Rating Scale, Fourth Edition (ADHD-RS-IV) (DuPaul et al. 1998)
total or subscale score ‡90th percentile relative to the general popu-
lation by age and sex was required at screening or baseline. In addi-
tion, an Estimate Full Scale intellectual level ‡80 on the four-subtest
form of the Wechsler Abbreviated Scale of Intelligence (Axelrod
2002) was required. Severe concomitant psychiatric disease or
chronic medical illness were reasons for exclusion (Wigal et al. 2015).
MPH-MLR (Rhodes Pharmaceuticals L.P., Coventry, RI) (Ap-
tensio XR 2015) is an extended-release formulation of methyl-
phenidate that was approved in 2015 by the U.S. Food and Drug
Administration. MPH-MLR given once daily in capsule form or
sprinkled on applesauce demonstrates a biphasic release that in-
cludes a first peak at *2 hours following administration and a
second attenuated peak at *8 hours post administration, and sus-
tained levels through at least hour 12 (Adjei et al. 2014). The two
pivotal studies of MPH-MLR showed a positive benefit of treat-
ment on symptoms of ADHD in children and adolescents (Wigal
et al. 2014, 2015). Symptomatic response and remission with MPH-
MLR have been described previously (Mattingly et al. 2017).
Functional outcomes were assessed in the larger MPH-MLR piv-
otal study (Wigal et al. 2015) as a secondary outcome. We evalu-
ated the functional characteristics of children and adolescents with
ADHD enrolled in this study and compared the relationship
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between clinical response or remission and functional outcomes
after 11 weeks of open-label treatment with MPH-MLR.
The study protocol, amendments, and informed consent form
were reviewed and approved by an institutional review board for
each study site. The study was conducted in compliance with Good
Clinical Practice guidelines of the International Conference on
Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use, the United States Code of Federal
Regulations that relates to clinical trial conduct, and the principles
of the Declaration of Helsinki. All enrollees and/or their guardian
provided informed consent before screening assessments.
Functional and symptom assessment
The WFIRS-Parent (WFIRS-P) and ADHD-RS-IV were as-
sessed at baseline (beginning of double-blind phase), end of double
blind, and end of open label.
WFIRS-P is a parent-rating scale that assesses functional im-
pairment in the following domains: Family; Learning and School
(including subdomains of Learning and Behavior); Life Skills;
Child’s Self-concept; Social Activities; and Risky Activities
(Canadian ADHD Resource Alliance [CADDRA], 2011). WFIRS-P
uses a 50-item scale, with each item rated on the following 4-point
scale: 0 = never or not at all; 1 = sometimes or somewhat; 2 = often or
much; and 3 = very often or very much or NA = not applicable
(Canadian ADHD Resource Alliance 2000). The total score is the
mean score for all items and the domain score is the mean score of
the items in each domain. The WFIRS-P has shown strong psy-
chometric properties in clinical settings (Tarakçıoğlu et al. 2015),
research populations (Gajria et al. 2015), and population samples
(Hadianfard et al. 2017). Internal consistency was demonstrated by
alpha >0.9 for the measure as a whole and >0.7 for all domains
(Gajria et al. 2015); test–retest reliability was evidenced by r > 0.7
after 1–4 weeks; moderate to strong correlations between each
domain and the scale as a whole; and confirmatory factor analysis
of the domains (Weiss et al. 2005, 2007; Molina et al. 2009; Qian
et al. 2011; Gajria et al. 2015; Punyapas et al. 2015; Tarakçıoğlu
et al. 2015; Dose et al. 2016; Hadianfard et al. 2017).
The minimal important difference (MID) of a clinically mean-
ingful change over time for the WFIRS-P is a mean score of 0.25, as
determined by use of three different methods (1/2 standard devia-
tion [SD], standard error of the mean, and patient anchors of when
they saw a significant change) (Hodgkins et al. 2016). This can be
considered a reasonable and empirically derived definition of a
clinically significant improvement. The receiver operating char-
acteristics that differentiate patients with ADHD from community
controls with the optimal area under the curve is a mean score of
0.65 (Thompson et al. 2017). Since this represents a value that
places the patient in a domain of functional impairment no different
from the population without ADHD, it is a reasonable and empir-
ically derived definition of functional remission. The objective of
this study is to determine the extent to which children and ado-
lescents who meet the conventional definitions for symptom im-
provement and remission also meet empirical criteria for functional
improvement and remission. Previous clinical trials have demon-
strated that the WFIRS-P is sensitive to change in functional im-
pairment (Banaschewski et al. 2013, 2014; Stein et al. 2015; Wilens
et al. 2015; Nagy et al. 2016) and sensitive to change as measured
against change in ADHD symptoms (Gajria et al. 2015).
The ADHD-RS-IV is an 18-item scale that rates each of the
symptoms of ADHD as outlined in the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition Text Revision (DSM-
IV-TR) (DuPaul et al. 1998). Response to an ADHD treatment
has been defined as an improvement in the ADHD-RS-IV of ‡30%,
with remission defined as no longer meeting the ADHD diagnostic
criteria (ADHD-RS-IV score £18) (Steele et al. 2006).
Definitions
For these analyses, the following definitions were applied: (1)
symptom improvement was defined as a ‡30% decrease (improve-
ment) in ADHD-RS-IV total score; (2) symptom remission was
defined as an ADHD-RS-IV total score £18; (3) functional im-
provement was defined as a decrease in WFIRS-P total score ‡0.25
(MID); and (4) functional remission was defined as a WFIRS-P total
score £0.65. It should be noted that Mattingly et al. (2017) previously
demonstrated that a 30% decrease in symptoms (measured by
ADHD-RS-IV total) and a CGI-I score of either much or very much
improved were comparable definitions of improvement. Similarly, in
the same study, it was found that a 50% decrease in symptoms or a
mean total score on the ADHD-RS-IV of £18 was also a comparable
definition of symptom remission.
Statistical analysis
Exact confidence intervals for proportions were used. Effect size
for reduction in WFIRS-P total score was defined as the mean
reduction divided by the SD at baseline. For studies with one-
group, pre-post designs, the pre-group mean is usually subtracted
from the post-group mean and divided by the SD at pre. (Durlak
2009). A two-sample t-test was used to compare treatment naive
with nontreatment naive and to compare children with adolescents.
Results
A total of 221 children and adolescents entered and 200 completed
the open-label phase. The population was mostly white, male, and
had a mean (SD) age of 10.8 (3.0) years and mean (SD) weight of
45.0 (19.4) kg. The most prevalent ADHD presentation was com-
bined (134/221, or 61%), with predominantly inattentive being most
of the remaining children and adolescents (72/221, or 33%).
At baseline, mean ADHD-RS-IV total scores for treatment naive
(n = 148) were similar to those for previously treated (n = 73; 36.0 vs.
36.4; p = 0.77); mean WFIRS-P total score indicated more functional
impairment for treatment naive (0.82 vs. 0.70, p = 0.02; Table 1). The
domains and subdomains with significant differences were Learn-
ing and School (1.18 vs. 0.84, p < 0.001), Learning (1.94 vs. 1.31,
p < 0.001), and Life Skills (1.03 vs. 0.87, p = 0.02). WFIRS-P total
and individual domain scores were similar for children and ado-
lescents. Functional impairment was prevalent across WFIRS-P
domains, with the greatest impairment in the Learning domain
(Learning 1.73, Learning and School 1.07, Family 0.81, School
Behavior 0.62, Life Skills 0.98, Self-concept 0.82, Social Activ-
ities 0.64, and Risky Activities 0.36; Fig. 1).
At the end of the open-label phase, statistically and clinically
significant improvement in total and all functional domains was
noted, with the largest improvement in the Learning domain (Fig. 2).
Mean (SD) change from baseline in WFIRS-P score at the end of the
open-label phase was as follows: total 0.27 (0.32), Family 0.27
(0.47), Learning and School 0.50 (0.56), Learning 0.74 (0.83), Be-
havior 0.44 (0.53), Life Skills 0.25 (0.47), Self-concept 0.41 (0.73),
Social Activities 0.24 (0.43), and Risky Activities 0.18 (0.33). With
the exception of Family, effect size for all domains was ‡0.50, and
Total, Learning/School, and Learning had effect sizes ‡0.75.
WFIRS-P AND MPH-MLR IN CHILDREN WITH ADHD 523
Overall, at open-label end, 94% (188/200) of patients had symp-
tom improvement (‡30% ADHD-RS-IV total score improvement)
and 56% (112/200) had functional improvement (‡0.25 decrease in
WFIRS-P total score). Of those with symptom improvement, only
57% (108/188) had functional improvement (Fig. 3) and 43% (80/
188) did not have functional improvement. With 95% assurance,
‡35% of patients with symptom improvement will not have func-
tional improvement (95% confidence interval, 0.35–0.50). By con-
trast, of the 112 patients with functional improvement, only 4% did
not have symptom improvement.
At open-label end, 75% (150/200) of children and adolescents
were in symptom remission as defined by ADHD-RS-IV total score
£18. This was similar to 74% (147/200) with functional remission,
defined as WFIRS-P total score £0.65. Of the 150 children and
adolescents with symptom remission at the end of the open-label
phase, 19% (29/150) were not in functional remission (WFIRS-P
total score >0.65; Fig. 4). Of the 147 with functional remission,
18% (26/147) did not have symptom remission.
Discussion
Treatment with MPH-MLR in children and adolescents who were
functionally impaired resulted in significant improvements in
WFIRS-P total score and all domains. The population of children and
adolescents in this study had the most impairment in the Learning
domain and experienced the greatest improvement in this area.
In our study, symptomatic improvement was noted in almost all
children and adolescents and symptomatic remission was noted in a
FIG. 1. WFIRS-P scores at baseline and end of the OL phase. OL, open-label; SD, standard deviation; WFIRS-P, Weiss Functional
Impairment Rating Scale-Parent.
Table 1. Weiss Functional Impairment Rating Scale-Parent Score at Baseline by Attention-Deficit/Hyperactivity
Disorder Treatment Status Before Study Entry and Age Group
Treatment naive (n = 148a) Not treatment naive (n = 73) Childb (n = 152c) Adolescentd (n = 69)
WFIRS-P, mean (SD)
Total* 0.82 (0.33) 0.70 (0.37) 0.78 (0.35) 0.79 (0.35)
Family 0.83 (0.60) 0.78 (0.60) 0.83 (0.61) 0.77 (0.59)
Learning and School 1.18 (0.60) 0.84 (0.60) 1.05 (0.58) 1.13 (0.69)
Learning 1.94 (0.84) 1.31 (0.89) 1.69 (0.89) 1.82 (0.93)
Behavior 0.66 (0.63) 0.53 (0.58) 0.59 (0.56) 0.66 (0.73)
Life Skills 1.03 (0.44) 0.87 (0.46) 0.94 (0.46) 1.05 (0.43)
Child’s Self-concept 0.85 (0.70) 0.77 (0.77) 0.82 (0.73) 0.84 (0.71)
Social Activities 0.64 (0.46) 0.63 (0.49) 0.68 (0.49) 0.56 (0.41)
Risky Activities 0.36 (0.34) 0.34 (0.31) 0.36 (0.34) 0.35 (0.31)
aN = 147 (Family, Child’s Self-concept, and Risky Activities), N = 146 (Behavior).
bAge 6–12 years inclusive.
cN = 151 (Family, Child’s Self-concept, and Risky Activities), N = 150 (Behavior).
dThirteen to 18 years inclusive.
*p = 0.02 treatment naive versus not treatment naive.
SD, standard deviation; WFIRS-P, Weiss Functional Impairment Rating Scale-Parent.
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FIG. 2. Mean reduction in WFIRS-P score from baseline to end of the OL phase. ES, effect size (defined as mean reduction divided by
standard deviation at baseline). *p < 0.001.
FIG. 3. Proportion of children and adolescents with functional improvement by symptom improvement* at end of the open-label
phase. *Symptom improvement defined as ‡30% improvement in ADHD-RS-IV total score from baseline to end of the open-label
phase; functional improvement defined as ‡0.25 improvement in WFIRS-P total score from baseline to end of the open-label phase
(n = 200 at end of the open-label phase). ADHD-RS-IV, Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition.
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majority of the study population. Only 57% of the population
studied, who had symptom improvement also showed functional
improvement, while 96% of those who had functional improvement
also had symptom improvement. This lack of complete alignment
between symptom improvement/remission and functional im-
provement/remission cannot be explained solely by the concept
that functional impairment is driven by factors other than ADHD,
because almost all of those who reached the defined measure of
functional remission also had symptom remission. Alignment be-
tween these measures would be expected and consistent with the
definition of functional impairment used in the WFIRS-P, de-
scribing difficulties in functioning secondary to the symptoms of
the disorder. Even for patients in symptomatic remission, however,
assessment of functional impairment remains clinically significant.
It should be noted that using the WFIRS-P MID definition of
0.25 for improvement and the receiver operating characteristics
definition of 0.65 as the cutoff that differentiates ADHD from
normal controls means that remission is not necessarily a more
robust indicator of response than improvement. The population had
enough children with mild impairment that 74% met the criteria for
remission based on endpoint score, while only 56% met the criteria
for improvement based on the degree of change. Further research is
necessary to look at how these empirically based definitions of
improvement compare to definitions of functional improvement
and response similar to those used for symptoms based just on
change, that is, a 30% versus 50% change in score and improve-
ment versus remission outcomes in samples that have more severe
functional impairment.
Medication treatment of children and adolescents with ADHD has
resulted in improvements in functioning. In a placebo-controlled
comparison study of the dose effects of extended-release dex-
methylphenidate and extended-release mixed amphetamine salts,
the WFIRS-P was used to evaluate functional response to 8 weeks
of treatment in 56 children and adolescents with ADHD (Stein et al.
2011). Statistically significant dose effects were noted in WFIRS-P
total ( p = 0.008) and the Family ( p = 0.001), Learning ( p = 0.002),
Social Activities ( p = 0.018), and Risk-Taking ( p = 0.050) subscales
that were similar for the two study drugs, with no impact of treatment
noted for the Living Skills or Self-Esteem subscales. Dose-related
symptom improvements also were noted in this study using both the
ADHD-RS-IV and the CGI-I.
In this study, gains were seen in all domains, with the most robust
improvement seen in School Learning, which was also the domain
most impaired at baseline in this particular sample. These results are
consistent with other trials. The domain of Risky Activities has
somewhat lower baseline scores than other domains, and taps rare,
but salient events that may have high clinical impact even if there are
floor effects or lower values than the absolute scores. Some authors
(Dose et al. 2016) have assumed that the domain of Risky Activities
is not relevant to a younger population. However, our data demon-
strate not only that the domain is relevant, but also that improvement
in this domain may have significant impact on the high-risk outcomes
of children and adolescents with ADHD.
The WFIRS-P was used to evaluate functional impairment in a
7-week, randomized, double-blind, placebo-controlled evaluation
of lisdexamfetamine or OROS methylphenidate as reference in
children and adolescents with ADHD (Banaschewski et al. 2013).
For lisdexamfetamine-treated patients, there was evidence of func-
tional improvement, evidenced by statistically significant changes in
WFIRS-P by week 4 (Total, Learning and School, Social Activities,
and Risky Activities), and by week 7 in the remaining domains.
OROS methylphenidate–treated patients followed a similar pattern.
In the primary evaluation of these data, significant improvements in
ADHD-RS-IV scores were noted in both study treatment groups
(Coghill et al. 2013).
Comparison of stimulant versus nonstimulant outcomes in func-
tional impairment suggests a more robust improvement in functional
impairment with stimulants. In that same study, lisdexamfetamine
FIG. 4. Proportion of children and adolescents with functional remission* by symptom remission at end of the OL phase. *Remission
defined as ADHD-RS-IV total score £18 (symptom) or WFIRS-P total score £0.65 (functional).
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showed more robust improvement than OROS methylphenidate and
atomoxetine (Coghill et al. 2017). This may reflect the increased
parent perception of difference in outcome based on clear demar-
cations between periods on and off medication. It should be noted
that in this study of a long-acting methylphenidate product, robust
improvement was shown in all domains in open-label follow-up,
consistent with the outcomes of lisdexamfetamine. This study also
confirms the hypothesis laid out by Coghill et al. (2017) that neither
symptom evaluation nor functional evaluation alone are sufficient to
allow the clinician to make appropriate decisions about whether and
what further intervention is required.
In summary, our study replicates previous studies in demon-
strating that treatment with medication leads to improvement in
both symptoms and functional impairment. Our findings are unique
in that we have been able to show that a significant fraction of
children with symptom improvement and remission with stimulant
medication may continue to show functional impairment, war-
ranting further clinical intervention.
Limitations
This article presents the results of a post hoc analysis. Only a
very small percentage of the population was predominantly hy-
peractive ADHD subtype and results may or may not be applicable
to this subtype. Although we have used reasonable psychometric
and empirically derived overall scores of functional improvement
and functional remission, it is possible for children to show over-
all improvement, but still experience impairment in a particular
domain, or conversely to show dramatic and clinically significant
improvement in a domain that is not sufficient to meet the cutoff
of 0.25 for the scale as a whole. Similarly, the definition we used
for functional remission is based on the cutoff score that differen-
tiates ADHD from normal controls, but cannot be taken to mean
that the child has no residual impairment. The study results reported
are open label, and therefore the extent to which functional im-
provement was driven by treatment as opposed to time is unclear.
However, the results appear to be largely consistent with the ex-
pected gains in functional impairment seen with change in symp-
toms, and there is little to suggest that children with ADHD show
systematic gains in functioning with time alone. The greatest gains
seen were in domains of School and Learning, but this was based
on parent report since no teacher evaluations were included. Since
there is modest correlation between teacher and parent report, and
teachers typically report greater change at school than parents,
these results may be an underestimate of the response seen in the
school setting. In addition, because this is an open-label single-
group study, the effect sizes should be interpreted with caution.
Conclusions
Treatment with MPH-MLR resulted in improvement on the total
score and all domain scores of the WFIRS-P as well as functional
remission in 74% of children and adolescents. Approximately half
of the children and adolescents who achieved symptom improve-
ment (30% change in ADHD-RS-IV) also achieved functional
improvement, and symptom remission (mean score £18) was as-
sociated with an achievement of functional remission in >80% of
children and adolescents. This suggests that targeting remission
as a goal of symptom response has a direct impact on real-life
gains in function. These results highlight the need to assess im-
provement and remission of both symptoms and functioning in
clinical studies. Additional therapeutic modalities may be needed
in children and adolescents with persistent functional impairment
despite symptom normalization, and additional therapeutic in-
terventions may be required.
Clinical Significance
Both symptom improvement and functional improvement as
well as symptom and functional remission were observed in chil-
dren treated with MPH-MLR. Seventy-five percent of children
achieved symptom remission and 74% achieved functional remis-
sion. Functional remission was achieved in >80% of those with
symptom remission. Targeting remission as a goal of symptom re-
sponse appears to have a direct impact on real-life gains in function
and suggests that clinical studies need to assess improvement and
remission of both symptoms and functioning.
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